

07<sup>th</sup> August, 2023

The Dy. General Manager (Listing Dept.) BSE Limited, Corporate Relationship Dept., 1<sup>st</sup> Floor, New Trading Ring, P. J. Towers, Dalal Street, Fort, Mumbai - 400 001

(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

## Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter ended 30<sup>th</sup> June, 2023

The presentation on unaudited Consolidated Financial Results for the quarter ended  $30^{th}$  June, 2023 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI COMPANY SECRETARY

Encl: A/a

\_\_\_\_\_



Q1 FY 2023-24

Revenues: Summary



## **Revenue: Summary**

Revenues (Rs cr)	Q1 FY24	Q1 FY23	Gr%
India	1,426	1,245	15%
United States	293	299	-2%
Germany	258	214	21%
Brazil	190	184	3%
Other countries	293	252	16%
Others	131	154	-15%
Total	2,591	2,347	10%

